Key points from article :
World's first gene therapy trial for choroideremia recently completed.
Choroideremia, caused by a mutation in a gene called CHM and results in blindness.
In a 14 person trial, vision either maintained or improved for up to five years in every participant.
Spinal muscular atrophy is caused by a genetic flaw in the SMN1 gene.
This causes certain motoneurons to deteriorate prematurely.
Previously no treatment for SMA, and babies generally only lived a few years.
Spinraza gene modulation therapy can allow babies to develop normally.
